Uses
VIVJOA™ is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.
Source: US FDA prescribing information
- Presentations
- 1
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Oteseconazole is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential, among other approved uses. MedsAcross supplies Oteseconazole for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Azole Antifungal, Breast Cancer Resistance Protein Inhibitors
- ATC classification
- J02 Antifungals for systemic use
- US FDA first approval
- 26 April 2022
- EU status
- Application withdrawn
- Orphan designation
- No
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Oral
- Dosage forms
- Capsule
- Identifiers
- UNII VHH774W97NCAS 1340593-59-0DrugBank DB13055Q27291837
Clinical information
From the regulator-approved product information. Each section names its source.
How it works
Oteseconazole is an antifungal drug.
Source: US FDA prescribing information
Dosing overview
There are two recommended VIVJOA dosage regimens: a VIVJOA-only regimen and a Fluconazole/VIVJOA regimen. Use one of these two dosage regimens. Administer VIVJOA orally with food. For the VIVJOA-only Dosage Regimen: On Day 1: Administer VIVJOA 600 mg (as a single dose), then On Day 2: Administer VIVJOA 450 mg (as a single dose), then Beginning on Day 14: Administer VIVJOA 150 mg once a week (every 7 days) for 11 weeks (Weeks 2 through 12). For the Fluconazole/VIVJOA Dosage Regimen, prescribe fluconazole and: On Day 1, Day 4, and Day 7: Administer fluconazole 150 mg orally, then On Days 14 through 20: Administer VIVJOA 150 mg once daily for 7 days, then Beginning on Day 28: Administer VIVJOA 150 mg once a week (every 7 days) for 11 weeks (Weeks 4 through 14).
Source: US FDA prescribing information
Contraindications
VIVJOA is contraindicated in: Females of reproductive potential Pregnant and lactating women Patients with known hypersensitivity to oteseconazole. Females of Reproductive Potential,,. Pregnant and Lactating women,,. Hypersensitivity to oteseconazole
Source: US FDA prescribing information
Warnings and precautions
Embryo-Fetal Toxicity: Based on animal studies, VIVJOA may cause fetal harm. The drug exposure window of approximately 690 days (based on 5 times the half-life of oteseconazole) precludes adequate mitigation of the embryo-fetal toxicity risks. Advise patients that VIVJOA is contraindicated in females of reproductive potential, and in pregnant and lactating women because of potential risks to a fetus or breastfed infant.
Source: US FDA prescribing information
Side effects
The most frequently reported adverse reactions (incidence > 2%) were headache and nausea.
Source: US FDA prescribing information
Interactions
BCRP (Breast Cancer Resistance Protein) Substrates: Concomitant use of VIVJOA with BCRP substrates may increase the exposure of drugs that are BCRP substrates, which may increase the risk of adverse reactions associated with these drugs. Use the lowest possible starting dose of the BCRP substrate or consider reducing the dose of the substrate drugs and monitor for adverse reactions.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
1 presentations of Oteseconazole, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Vivjoa 150 mg capsuleOral | Mycovia Pharmaceuticals | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Questions and answers
Is Oteseconazole available for export from India?
Yes, on request. MedsAcross lists 1 presentations of Oteseconazole and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Oteseconazole have?
The catalogue lists 1 brand names for Oteseconazole, including Vivjoa.
Is Oteseconazole approved by the US FDA?
Yes. The US FDA first approved Oteseconazole on 26 April 2022, according to Drugs@FDA.
Does Oteseconazole need cold chain shipping?
No listed presentation of Oteseconazole is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Oteseconazole in?
Oteseconazole is classified under ATC code J02 (Antifungals for systemic use).
References
- VIVJOA prescribing information (Mycovia Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 8 January 2026
Request Oteseconazole for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.